AYLIDE 4 Glimepiride 4 mg tablet blister pack

国家: 澳大利亚

语言: 英文

来源: Department of Health (Therapeutic Goods Administration)

现在购买

下载 资料单张 (PIL)
24-08-2020
下载 产品特点 (SPC)
24-08-2020
下载 公众评估报告 (PAR)
01-12-2017

有效成分:

glimepiride

可用日期:

Alphapharm Pty Ltd

INN(国际名称):

Glimepiride

授权状态:

Registered

资料单张

                                AYLIDE
_contains the active ingredient glimepiride_
CONSUMER MEDICINE INFORMATION
WHAT IS IN THIS LEAFLET
This leaflet answers some common
questions about Aylide.
It does not contain all the available
information. It does not take the
place of talking to your doctor or
pharmacist.
All medicines have benefits and
risks. Your doctor has weighed the
risks of you taking Aylide against the
benefits expected for you.
IF YOU HAVE ANY CONCERNS ABOUT
TAKING THIS MEDICINE, TALK TO YOUR
DOCTOR OR PHARMACIST.
PLEASE READ THIS LEAFLET CAREFULLY
AND KEEP THIS LEAFLET WITH YOUR
MEDICINE.
You may need to read it again.
WHAT AYLIDE IS USED
FOR
Aylide is used to control high blood
sugar levels in people with type 2
diabetes mellitus.
This type of diabetes is also known
as non-insulin-dependent diabetes
mellitus (NIDDM) or maturity onset
diabetes.
Aylide is used when diet and exercise
are not enough to control your
condition. However, as Aylide does
not replace these, your doctor will
suggest that you continue with your
diet and exercise programs, while
you are taking Aylide.
Aylide contains the active ingredient
glimepiride, which belongs to a
group of medicines called
sulfonylureas.
These medicines work to lower blood
sugar levels by causing your
pancreas to release more insulin into
the blood stream.
ASK YOUR DOCTOR IF YOU HAVE ANY
QUESTIONS ABOUT WHY AYLIDE HAS
BEEN PRESCRIBED FOR YOU.
Your doctor may have prescribed
Aylide for another reason.
Aylide is not recommended for use in
children, as its safety and
effectiveness in this age group has
not been established.
Aylide is available only with a
doctor's prescription.
There is no evidence that Aylide is
addictive.
BEFORE YOU TAKE AYLIDE
_WHEN YOU MUST NOT TAKE IT_
DO NOT TAKE AYLIDE IF YOU ARE
ALLERGIC TO:
•
medicines containing glimepiride
(e.g. Amaryl)
•
any other sulfonylureas
•
related medicines such as sulfur
antibiotics (e.g. sulfonamides) or
thiazide diuretics
•
any of the ingredients listed at the
end of this leaflet.
Some of the symptoms of an allergic
reaction
                                
                                阅读完整的文件
                                
                            

产品特点

                                AYLIDE
®
_Glimepiride _
PRODUCT INFORMATION
NAME OF THE MEDICINE
Active ingredient:
Glimepiride
Chemical name:
trans-1-{4-[2- (3-ethyl-4-methyl- 2-oxo-3-pyrroline- 1 carboxamido)
ethyl]phenylsulfonyl}-3- (4-methylcyclohexyl) urea
Structural formula:
Molecular formula:
C
24
H
34
N
4
0
5
S
Molecular weight: 490.62
CAS Registry No.: 93479-97-1
DESCRIPTION
Glimepiride is a member of the sulfonylurea group of oral antidiabetic
agents. It is a white odourless,
crystalline powder, practically insoluble in methanol and water,
slightly soluble in ethanol and sparingly
soluble in methylene chloride.
Aylide is available as 1 mg, 2 mg, 3 mg and 4 mg tablets containing
glimepiride as the active ingredient.
Aylide tablets also contain the following inactive ingredients:
lactose monohydrate, povidone, cellulose -
microcrystalline, magnesium stearate, sodium starch glycollate, iron
oxide red CI77491 (1 mg tablet only), iron
oxide yellow CI77492 (2 mg and 3 mg tablets) and indigo carmine
CI73015 (2 mg and 4 mg tablets).
PHARMACOLOGY
PHARMACODYNAMICS
MECHANISM OF ACTION
Glimepiride is a sulfonylurea antidiabetic agent which decreases blood
glucose concentrations.
The primary mechanism of action of glimepiride appears to be dependent
on stimulating the release of insulin
from functioning pancreatic beta cells. Glimepiride acts in concert
with glucose by improving the sensitivity of
beta cells to physiological glucose stimulus, resulting in insulin
secretion in the rhythm of meals. In addition,
extrapancreatic effects (e.g. reduction of basal hepatic glucose
production and increased peripheral tissue
sensitivity to insulin and glucose uptake) may also play a limited
role in the activity of glimepiride.
In non-fasting diabetic patients, the hypoglycaemic action of a single
dose of glimepiride persists for 24 hours.
Evidence from
_ in vitro_
and animal studies suggests that there is lower glucagon secretion
with glimepiride than
glibenclamide and this may give rise to a prolonged reduction of blood
glucose levels without increased pl
                                
                                阅读完整的文件
                                
                            

搜索与此产品相关的警报